0000899243-20-020565.txt : 20200728 0000899243-20-020565.hdr.sgml : 20200728 20200728181109 ACCESSION NUMBER: 0000899243-20-020565 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200728 FILED AS OF DATE: 20200728 DATE AS OF CHANGE: 20200728 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: ALEXION PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0000899866 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39397 FILM NUMBER: 201055056 BUSINESS ADDRESS: STREET 1: 121 SEAPORT BOULEVARD CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 4752302596 MAIL ADDRESS: STREET 1: 121 SEAPORT BOULEVARD CITY: BOSTON STATE: MA ZIP: 02210 FORMER NAME: FORMER CONFORMED NAME: ALEXION PHARMACEUTICALS INC DATE OF NAME CHANGE: 19960111 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Inozyme Pharma, Inc. CENTRAL INDEX KEY: 0001693011 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 475129768 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 321 SUMMER STREET STREET 2: SUITE 400 CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 857-330-4340 MAIL ADDRESS: STREET 1: 321 SUMMER STREET STREET 2: SUITE 400 CITY: BOSTON STATE: MA ZIP: 02210 FORMER COMPANY: FORMER CONFORMED NAME: Inozyme Pharma, LLC DATE OF NAME CHANGE: 20161222 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-07-28 1 0001693011 Inozyme Pharma, Inc. INZY 0000899866 ALEXION PHARMACEUTICALS, INC. 121 SEAPORT BOULEVARD BOSTON MA 02210 0 0 1 0 Common Stock 2020-07-28 4 C 0 1109910 A 1109910 D Series A-2 Convertible Preferred Stock 2020-07-28 4 C 0 8294360 0.00 D Common Stock 1109910 0 D On July 28, 2020, the Series A-2 Convertible Preferred Stock automatically converted into Common Stock on a 7.4730-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. /s/ Douglas Barry, as Assistant Secretary of Alexion Pharmaceuticals, Inc. 2020-07-28